This four-year trial, a multi-site worldwide effort, will check three anti-amyloid-beta interventions: gantenerumab, solanezumab and a third, up to now undetermined, drug.?.. Cogstate test shows effective treatment choice for schizophrenia Medical technology company Cogstate continues to strengthen its position as an important partner for measuring cognition in essential studies all over the world, with results from a schizophrenia study using Cogstate's test published in a major scientific journal.Debbie Wasserman-Schultz , and Rep. Henry Cuellar ,’ your blog adds . Noting ‘President Obama officially started his second term in workplace this week,’ the Global Wellness Technology Coalition's ‘Breakthroughs’ blog page ‘offer[s] a roundup of probably the most critical leadership adjustments that could affect financing and guidelines for global health insurance and international development applications’ . This content was reprinted from kaiserhealthnews.org with permission from the Henry J.